科利吉姆制药
COLL
23.19
+0.01
+0.04%
科利吉姆制药
US · COLL
#3535 按市值排名
上市于 2015
23.19
+0.01
+0.04%
实时 - 追踪5344个代码 - 心跳于217秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例上升了1.3个百分点。
机构持股
- 机构持股比例
- 126.77% +1.26pp
- 机构数量
- 340 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund98.14%
Hedge Fund20.73%
Public Company4.77%
Government Pension Fund1.23%
Individual/Insider1.12%
Private Company0.75%
Family Office/Trust0.38%
Insurance Company0.36%
Bank/Investment Bank0.26%
主要股东 截至 2026-06-30
BlackRock
16.71% · 5.44M 股
Janus Henderson Group plc
6.60% · 2.15M 股
Millennium Management LLC
5.59% · 1.82M 股
Fuller & Thaler Asset Management, Inc.
5.02% · 1.63M 股
Principal Global Investors, LLC
5.01% · 1.63M 股
Vanguard Capital Management, LLC
4.95% · 1.61M 股
State Street Global Advisors
4.70% · 1.53M 股
MFS Investment Management
4.32% · 1.41M 股
Renaissance Technologies Corp.
4.20% · 1.37M 股
Eventide Asset Management, LLC
4.18% · 1.36M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 19次买入 · 30次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Colleen Tupper | Chief Financial Officer | 0.19% |
| John Fallon | Independent Director | 0.17% |
| Gino Santini | Lead Independent Director | 0.13% |
| Michael Heffernan | Chairperson | 0.13% |
| John Freund | Independent Director | 0.13% |
| Vikram Karnani | Chief Executive Officer | 0.12% |
| Thomas Smith | Chief Medical Officer | 0.11% |
| Rita Balice-Gordon | Independent Director | 0.06% |
| Gwen A. Melincoff | Independent Director | 0.04% |
| Nancy Lurker | Director | 0.03% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Scott Dreyer | Executive Vice President | Intent to Sell (Form 144) | -27,419 | $22.00 |
| 2026-07-16 | John Fallon | Independent Director | Intent to Sell (Form 144) | -13,920 | $35.73 |
| 2026-07-14 | John Fallon | Independent Director | Intent to Sell (Form 144) | -8,095 | $36.32 |
| 2026-06-07 | Gino Santini | Lead Independent Director | Derivative Exercise and Retained | +8,700 | $16.49 |
| 2026-05-17 | John Freund | Independent Director | Open Market Disposition | -20 | $34.05 |
| 2026-05-14 | John Freund | Independent Director | Derivative Exercise and Sale | -4,127 | $16.49–34.54 |
| 2026-05-14 | John Freund | Independent Director | Derivative Exercise and Retained | +4,573 | $16.49 |
| 2026-05-13 | John Freund | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Nancy Lurker | Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Garen Bohlin | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Gino Santini | Lead Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Carlos Paya | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Rita Balice-Gordon | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Michael Donovan | Independent Director | Other Acquisition | +17,482 | -- |
| 2026-05-12 | Nancy Lurker | Director | Open Market Disposition | -4,500 | $35.97 |
| 2026-05-10 | Garen Bohlin | Independent Director | Derivative Exercise and Sale | -8,700 | $16.49–37.18 |
| 2026-03-17 | David Dieter | Executive Vice President | Automatic Disposition | -13,976 | $34.92 |
| 2026-03-16 | David Dieter | Executive Vice President | Sale to Issuer | -8,840 | $35.72 |
| 2026-03-08 | David Dieter | Executive Vice President | Automatic Disposition | -6,224 | $36.65 |
| 2026-03-02 | Scott Dreyer | Executive Vice President | Automatic Disposition | -49,976 | $40.36–40.99 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:18 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
科利吉姆制药 讨论区 0 条评论